HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

John MacDougall Selected Research

Neoplasms (Cancer)

11/2021DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
12/2010Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.
7/2009Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).
6/2005Recombinant semaphorin 6A-1 ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


John MacDougall Research Topics

Disease

4Neoplasms (Cancer)
11/2021 - 06/2005
1Medulloblastoma
07/2009

Drug/Important Bio-Agent (IBA)

1InflammasomesIBA
11/2021
1Immune Checkpoint InhibitorsIBA
11/2021
1Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA
11/2021
1CytokinesIBA
11/2021
1tanespimycin (17AAG)IBA
12/2010
1Heat-Shock Proteins (Heat-Shock Protein)IBA
12/2010
1cyclopamineIBA
07/2009
1IPI-926IBA
07/2009
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
06/2005
1Messenger RNA (mRNA)IBA
06/2005
1Semaphorins (Semaphorin)IBA
06/2005

Therapy/Procedure

1Immunotherapy
11/2021
1Therapeutics
11/2021
1Aftercare (After-Treatment)
12/2010
1Oral Administration
07/2009